Vismodegib, a second generation cyclopamine derivative, was approved by the FDA in 2012 as the first Shh inhibitor for BCC treatment.374,411 Vismodegib achieved satisfactory results in clinical trials in patients with locally advanced and metastatic BCC. The gene discussed is SHH; the disease is skin basal cell carcinoma.